Cargando…
Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD
BACKGROUND: Asthma and COPD are complex, heterogeneous conditions comprising a wide range of phenotypes, some of which are refractory to currently available treatments. Elucidation of these phenotypes and identification of biomarkers with which to recognize them and guide appropriate treat-ment rema...
Autores principales: | Kostikas, Konstantinos, Brindicci, Caterina, Patalano, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225326/ https://www.ncbi.nlm.nih.gov/pubmed/29437007 http://dx.doi.org/10.2174/1389450119666180212120012 |
Ejemplares similares
-
The asthma–COPD overlap syndrome: do we really need another syndrome in the already complex matrix of airway disease?
por: Kostikas, Konstantinos, et al.
Publicado: (2016) -
Eosinophilic Asthma, Phenotypes-Endotypes and Current Biomarkers of Choice
por: Porpodis, Konstantinos, et al.
Publicado: (2022) -
COPD treatment choices based on blood eosinophils: are we there yet?
por: Oliver, Brian, et al.
Publicado: (2019) -
Evaluation of exacerbations and blood eosinophils in UK and US COPD populations
por: Vogelmeier, Claus F., et al.
Publicado: (2019) -
Patient-Reported Outcomes (PROs) in COPD Clinical Trials: Trends and Gaps
por: Afroz, Nuzhat, et al.
Publicado: (2020)